Westend Partners’s AbbVie ABBV Stock Holding History

Westend Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	$17K	Buy	+350	New	+$15.5K	0.02%	83

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Westend Partners's ABBV Position: Q3 2013 in Review

Westend Partners opened a new position in AbbVie (ABBV) in Q3 2013: 350 shares worth $17K. The stake represents 0.02% of the portfolio and ranks #83 among its holdings.

1,297 funds tracked by Wall St. Rank hold ABBV as of Q3 2013.

Westend Partners held 350 shares of AbbVie worth $17K as of Q3 2013.
AbbVie was a new Westend Partners position in Q3 2013.
AbbVie made up 0.02% of Westend Partners's portfolio in Q3 2013, its #83 holding.
1,297 funds tracked by Wall St. Rank held AbbVie as of Q3 2013.

Based on Westend Partners's 13F filing for Q3 2013, filed 13 Nov 2013.